Skip to main content
SpringerLink
Log in

Prognostic and Predictive Value of TP53 Mutations in Human Cancer

  • Chapter
25 Years of p53 Research

Finding reliable molecular markers for early diagnosis, prognosis and prediction of response to treatment is a major challenge for cancer management. A marker of prognosis provides information on the risk of relapse and death independently of treatment, whereas a predicitve marker provides information on the potential benefit of a specific treatment (Lonning, 2003). An early diagnostic marker helps to identify lesions at high risk of malignant transformation. Clinical stage, tumor size and morphological grade are the most reliable factors of prognosis. Among numerous molecular markers that have been tested most recently, only a few are used in clinical practice. In breast cancer for example, estrogen and progesterone receptors are used routinely as predictive markers for tumor response to anti-hormone therapy. However, about 30 % of patients with positive receptor status (expected to benefit from anti-hormone treatment) will face a therapeutic failure, showing the limitations of these markers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE. 1996. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811-814.

    Article  CAS  PubMed  Google Scholar 

  • Ahrendt SA, Halachmi S, Chow JT, Wu L, Halachmi N, Yang SC, Wehage S, Jen J, Sidransky D. 1999. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci U S A 96:7382-7387.

    Article  CAS  PubMed  Google Scholar 

  • Ahrendt SA, Hu Y, Buta M, McDermott MP, Benoit N, Yang SC, Wu L, Sidransky D. 2003. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst 95:961-970.

    Article  CAS  PubMed  Google Scholar 

  • Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. 2000. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 6:3923-3931.

    CAS  PubMed  Google Scholar 

  • Aurelio ON, Kong XT, Gupta S, Stanbridge EJ. 2000. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol Cell Biol 20:770-778.

    Article  CAS  PubMed  Google Scholar 

  • Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T. 2003. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387-402.

    Article  CAS  PubMed  Google Scholar 

  • Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. 1995. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1:1029-1034.

    Article  CAS  PubMed  Google Scholar 

  • Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganas M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG. 2000. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 60:2155-2162.

    CAS  PubMed  Google Scholar 

  • Berns EM, van Staveren IL, Look MP, Smid M, Klijn JG, Foekens JA. 1998. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer 77:1130-1136.

    CAS  PubMed  Google Scholar 

  • Borresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E. 1998. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 4:203-210.

    CAS  PubMed  Google Scholar 

  • Borresen AL, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S,. 1995. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 14:71-75.

    Article  CAS  PubMed  Google Scholar 

  • Cadwell C and Zambetti GP. 2001. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 277:15-30.

    Article  CAS  PubMed  Google Scholar 

  • Caron dF, May-Levin F, Mouriesse H, Lemerle J, Chandrasekaran K, May P. 1987. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 39:185-189.

    Article  Google Scholar 

  • Casson AG, Evans SC, Gillis A, Porter GA, Veugelers P, Darnton SJ, Guernsey DL, Hainaut P. 2003. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. J Thorac Cardiovasc Surg 125:1121-1131.

    Article  CAS  PubMed  Google Scholar 

  • Chitemerere M, Andersen TI, Holm R, Karlsen F, Borresen AL, Nesland JM. 1996. TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Breast Cancer Res Treat 41:103-109.

    Article  CAS  PubMed  Google Scholar 

  • Crawford LV, Pim DC, Bulbrook RD. 1982. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30:403-408.

    Article  CAS  PubMed  Google Scholar 

  • de Anta JM, Jassem E, Rosell R, Martinez-Roca M, Jassem J, Martinez-Lopez E, Monzo M, Sanchez-Hernandez JJ, Moreno I, Sanchez-Cespedes M. 1997. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene 15:2951-2958.

    Article  PubMed  CAS  Google Scholar 

  • Di Como CJ, Gaiddon C, Prives C. 1999. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 19:1438-1449.

    PubMed  Google Scholar 

  • Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ. 1993. Gain of function mutations in p53. Nat Genet 4:42-46.

    Article  CAS  PubMed  Google Scholar 

  • Dumont P, Leu JI, Della PA, III, George DL, Murphy M. 2003. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365.

    Article  CAS  PubMed  Google Scholar 

  • Erber R, Conradt C, Homann N, Enders C, Finckh M, Dietz A, Weidauer H, Bosch FX. 1998. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 16:1671-1679.

    Article  CAS  PubMed  Google Scholar 

  • Fearon ER and Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61:759-868.

    Article  CAS  PubMed  Google Scholar 

  • Gasco M and Crook T. 2003. p53 family members and chemoresistance in cancer: what we know and what we need to know. Drug Resist Updat 6:323-328.

    Article  CAS  PubMed  Google Scholar 

  • Geisler S, Borresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G, Lonning PE. 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5- fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 9:5582-5588.

    CAS  PubMed  Google Scholar 

  • Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Borresen-Dale AL. 2001. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61:2505-2512.

    CAS  PubMed  Google Scholar 

  • Gentile M, Jungestrom MB, Olsen KE, Soderkvist P, Wingren S. 1999. p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation. Eur J Cancer 35:1202-1207.

    Article  CAS  PubMed  Google Scholar 

  • Goh HS, Yao J, Smith DR. 1995. p53 point mutation and survival in colorectal cancer patients. Cancer Res 55:5217-5221.

    CAS  PubMed  Google Scholar 

  • Hainaut P and Hollstein M. 2000. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77:81-137.

    Article  CAS  PubMed  Google Scholar 

  • Hashimoto T, Tokuchi Y, Hayashi M, Kobayashi Y, Nishida K, Hayashi S, Ishikawa Y, Tsuchiya S, Nakagawa K, Hayashi J, Tsuchiya E. 1999. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res 59:5572-5577.

    CAS  PubMed  Google Scholar 

  • Hawkins NJ, Gorman P, Tomlinson IP, Bullpitt P, Ward RL. 2000. Colorectal carcinomas arising in the hyperplastic polyposis syndrome progress through the chromosomal instability pathway. Am J Pathol 157:385-392.

    CAS  PubMed  Google Scholar 

  • Huang C, Taki T, Adachi M, Konishi T, Higashiyama M, Miyake M. 1998. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene 16:2469-2477.

    Article  CAS  PubMed  Google Scholar 

  • Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ, Harris CC. 2000. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 60:3333-3337.

    CAS  PubMed  Google Scholar 

  • Hussain SP, Amstad P, Raja K, Sawyer M, Hofseth L, Shields PG, Hewer A, Phillips DH, Ryberg D, Haugen A, Harris CC. 2001. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. Cancer Res 61:6350-6355.

    CAS  PubMed  Google Scholar 

  • Ishioka C, Englert C, Winge P, Yan YX, Engelstein M, Friend SH. 1995. Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. Oncogene 10:1485-1492.

    CAS  PubMed  Google Scholar 

  • Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. 2003. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 100:8424-8429.

    Article  CAS  PubMed  Google Scholar 

  • Kihara C, Seki T, Furukawa Y, Yamana H, Kimura Y, van Schaardenburgh P, Hirata K, Nakamura Y. 2000. Mutations in zinc-binding domains of p53 as a prognostic marker of esophageal-cancer patients. Jpn J Cancer Res 91:190-198.

    CAS  PubMed  Google Scholar 

  • Kressner U, Inganas M, Byding S, Blikstad I, Pahlman L, Glimelius B, Lindmark G. 1999. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 17:593-599.

    CAS  PubMed  Google Scholar 

  • Kucera E, Speiser P, Gnant M, Szabo L, Samonigg H, Hausmaninger H, Mittlbock M, Fridrik M, Seifert M, Kubista E, Reiner A, Zeillinger R, Jakesz R. 1999. Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group. Eur J Cancer 35:398-405.

    Article  CAS  PubMed  Google Scholar 

  • Laken SJ, Jackson PE, Kinzler KW, Vogelstein B, Strickland PT, Groopman JD, Friesen MD. 1998. Genotyping by mass spectrometric analysis of short DNA fragments. Nat Biotechnol 16:1352-1356.

    Article  CAS  PubMed  Google Scholar 

  • Lane DP and Benchimol S. 1990. p53: oncogene or anti-oncogene? Genes Dev 4:1-8.

    Article  CAS  PubMed  Google Scholar 

  • Livni N, Eid A, Ilan Y, Rivkind A, Rosenmann E, Blendis LM, Shouval D, Galun E. 1995. p53 expression in patients with cirrhosis with and without hepatocellular carcinoma. Cancer 75:2420-2426.

    Article  CAS  PubMed  Google Scholar 

  • Lonning PE. 2003. Study of suboptimum treatment response: lessons from breast cancer. Lancet Oncol 4:177-185.

    Article  PubMed  Google Scholar 

  • Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. 1994. p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810.

    Article  CAS  PubMed  Google Scholar 

  • Mandard AM, Hainaut P, Hollstein M. 2000. Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res 462:335-342.

    Article  CAS  PubMed  Google Scholar 

  • Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PW, Crook T, Kaelin WG, Jr. 2000. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25:47-54.

    Article  CAS  PubMed  Google Scholar 

  • Milner J, Medcalf EA, Cook AC. 1991. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol Cell Biol 11:12-19.

    CAS  PubMed  Google Scholar 

  • Montesano R, Hainaut P, Hall J. 1997. The use of biomarkers to study pathogenesis and mechanisms of cancer: oesophagus and skin cancer as models. IARC Sci Publ :291-301.

    Google Scholar 

  • Monti P, Campomenosi P, Ciribilli Y, Iannone R, Aprile A, Inga A, Tada M, Menichini P, Abbondandolo A, Fronza G. 2003. Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene 22:5252-5260.

    Article  CAS  PubMed  Google Scholar 

  • Moshinsky DJ and Wogan GN. 1997. UV-induced mutagenesis of human p53 in a vector replicated in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 94:2266-2271.

    Article  CAS  PubMed  Google Scholar 

  • Nagai MA, Schaer BH, Zago MA, Araujo SW, Jr., Nishimoto IN, Salaorni S, Guerreiro Costa LN, Silva AM, Caldas Oliveira AG, Mourao NM, Brentani MM. 2003. TP53 mutations in primary breast carcinomas from white and African-Brazilian patients. Int J Oncol 23:189-196.

    CAS  PubMed  Google Scholar 

  • O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ, Jr., Kohn KW. 1997. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300.

    PubMed  Google Scholar 

  • Oren M. 1992. p53: the ultimate tumor suppressor gene? FASEB J 6:3169-3176.

    CAS  PubMed  Google Scholar 

  • Ory K, Legros Y, Auguin C, Soussi T. 1994. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13:3496-3504.

    CAS  PubMed  Google Scholar 

  • Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR. 2000. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res 6:443-451.

    CAS  PubMed  Google Scholar 

  • Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, el Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF. 2001. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7:2984-2997.

    CAS  PubMed  Google Scholar 

  • Resnick MA and Inga A. 2003. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci U S A 100:9934-9939.

    Article  CAS  PubMed  Google Scholar 

  • Rose SL, Robertson AD, Goodheart MJ, Smith BJ, DeYoung BR, Buller RE. 2003. The impact of p53 protein core domain structural alteration on ovarian cancer survival. Clin Cancer Res 9:4139-4144.

    CAS  PubMed  Google Scholar 

  • Ryan KM and Vousden KH. 1998. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 18:3692-3698.

    CAS  PubMed  Google Scholar 

  • Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, Slattery ML. 2002. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 99:597-602.

    Article  CAS  PubMed  Google Scholar 

  • Scharer E and Iggo R. 1992a. Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res 20:1539-1545.

    Article  CAS  PubMed  Google Scholar 

  • Sigal A and Rotter V. 2000. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60:6788-6793.

    CAS  PubMed  Google Scholar 

  • Skaug V, Ryberg D, Kure EH, Arab MO, Stangeland L, Myking AO, Haugen A. 2000. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 6:1031-1037.

    CAS  PubMed  Google Scholar 

  • Smith-Sorensen B, Kaern J, Holm R, Dorum A, Trope C, Borresen-Dale AL. 1998. Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer 78:375-381.

    CAS  PubMed  Google Scholar 

  • Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de RM, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP, Borresen-Dale AL. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874.

    Article  CAS  PubMed  Google Scholar 

  • Soussi T. 2000. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60:1777-1788.

    CAS  PubMed  Google Scholar 

  • Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. 1998. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393:229-234.

    Article  CAS  PubMed  Google Scholar 

  • Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, Levine AJ, Sacchi A, Cesareni G, Oren M, Blandino G. 2000. Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 275:29503-29512.

    Article  CAS  PubMed  Google Scholar 

  • Takahashi M, Tonoki H, Tada M, Kashiwazaki H, Furuuchi K, Hamada J, Fujioka Y, Sato Y, Takahashi H, Todo S, Sakuragi N, Moriuchi T. 2000. Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int J Cancer 89:92-99.

    Article  CAS  PubMed  Google Scholar 

  • Taubert H, Meye A, Wurl P. 1996. Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res 56:4134-4136.

    CAS  PubMed  Google Scholar 

  • Temam S, Flahault A, Perie S, Monceaux G, Coulet F, Callard P, Bernaudin JF, St Guily JL, Fouret P. 2000. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 18:385-394.

    CAS  PubMed  Google Scholar 

  • Tomizawa Y, Kohno T, Fujita T, Kiyama M, Saito R, Noguchi M, Matsuno Y, Hirohashi S, Yamaguchi N, Nakajima T, Yokota J. 1999. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma [In Process Citation]. Oncogene 18:1007-1014.

    Article  CAS  PubMed  Google Scholar 

  • Tonisson N, Zernant J, Kurg A, Pavel H, Slavin G, Roomere H, Meiel A, Hainaut P, Metspalu A. 2002. Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. Proc Natl Acad Sci U S A 99:5503-5508.

    Article  CAS  PubMed  Google Scholar 

  • Tortola S, Marcuello E, Gonzalez I, Reyes G, Arribas R, Aiza G, Sancho FJ, Peinado MA, Capella G. 1999. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 17:1375-1381.

    CAS  PubMed  Google Scholar 

  • Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Trope CG, Abeler VM, Nesland JM, Borresen-Dale AL, Helland A. 2004. Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 24:21-34.

    Article  PubMed  CAS  Google Scholar 

  • Wikman FP, Lu ML, Thykjaer T, Olesen SH, Andersen LD, Cordon-Cardo C, Orntoft TF. 2000a. Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. Clin Chem 46:1555-1561.

    CAS  PubMed  Google Scholar 

  • Yamazaki Y, Chiba I, Hirai A, Sugiura C, Notani K, Kashiwazaki H, Tei K, Totsuka Y, Fukuda H. 2003. Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma. Oral Oncol 39:163-169.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. International Agency for Research on Cancer, World Health Organization, Lyon, France

    Magali Olivier & Pierre Hainaut

  2. Department of Genetics, The Norwegian Radium Hospital, Oslo, Norway

    Anne-Lise Børresen-Dale

Authors
  1. Magali Olivier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierre Hainaut
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne-Lise Børresen-Dale
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. International Agency for Research on Cancer, World Health Organization, Lyon, France

    Pierre Hainaut

  2. Cancer Center Karolinska, Karolinska Institute, Stockholm, Sweden

    Klas G. Wiman

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer

About this chapter

Cite this chapter

Olivier, M., Hainaut, P., Børresen-Dale, AL. (2007). Prognostic and Predictive Value of TP53 Mutations in Human Cancer. In: Hainaut, P., Wiman, K.G. (eds) 25 Years of p53 Research. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-2922-6_14

Download citation

Publish with us

Policies and ethics

Search

Navigation